This is a routine scientific disclosure with no near-term stock catalyst. The core value driver remains Evaxion's cash runway and clinical progress on its oncology pipeline, not this preclinical CMV data.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $3.20entry
- T+1 · 5mo ago +6.56%α +6.69% · $3.41
- T+5 · 4mo ago +3.44%α +3.18% · $3.31
- T+20 · 4mo ago −11.25%α −9.06% · $2.84
- T+60 · 8w ago +1.88%α −1.08% · $3.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced a poster presentation at the International Herpesvirus Workshop 2026 for its preclinical CMV vaccine candidate EVX-V1. The data will guide final antigen selection for this next-generation candidate, but this is an early-stage, non-clinical event with no financial terms, regulatory action, or near-term value inflection, simply a routine scientific conference disclosure for a preclinical program.
Key Facts
- Poster presentation of new preclinical data for EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
- EVX-V1 is a multi-component CMV vaccine candidate combining AI-discovered antigens with AI-optimized gB antigen.
- The data will guide final antigen selection for the vaccine candidate, no clinical timeline or regulatory milestone announced.
- No CMV vaccine has been approved to date; Evaxion remains at the preclinical stage for this program.
- Evaxion is a clinical-stage TechBio with ~$26M market cap and no approved products; cash-certainty is the primary concern.
Financial Impact
No financial figures provided, preclinical data presentation with no funding, deal value, or revenue impact.
Risk Factors
- CMV vaccine development is notoriously difficult, no approved vaccine exists despite decades of effort.
- Preclinical data does not guarantee progression to clinical trials; Evaxion may need additional capital to advance EVX-V1.
- Evaxion's ~$26M market cap and lack of revenue create binary financing risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320532 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers